thiophenes has been researched along with trametinib in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aktan, G; Allred, AJ; Becerra, CR; Cornfeld, M; Ferron-Brady, G; Gauvin, J; Ibrahim, N; Motwani, M; Orford, K; Papadopoulos, KP; Patnaik, A; Rasco, DW; Tolcher, AW | 1 |
| Bago-Horvath, Z; Fece de la Cruz, F; Haura, EB; Katz, AM; Kerzendorfer, C; Konopka, T; Loizou, JI; Mair, B; Mazouzi, A; Muellner, MK; Nagy-Bojarszky, K; Nijman, SM; Paz, K; Smida, M; Suchankova, T; Uras, IZ | 1 |
| Aleem, E; Arceci, RJ; Azorsa, DO; Bista, R; Henry, MM; Lee, DW; Patel, AR; Wai, DH | 1 |
| Chang, S; Choi, EA; Choi, YS; Kim, SC; Lee, EJ; Singh, SR | 1 |
1 trial(s) available for thiophenes and trametinib
| Article | Year |
|---|---|
Phase I study of the MEK inhibitor trametinib in combination with the AKT inhibitor afuresertib in patients with solid tumors and multiple myeloma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Dose-Response Relationship, Drug; Early Termination of Clinical Trials; Female; Humans; Male; MAP Kinase Kinase 1; MAP Kinase Kinase 2; Middle Aged; Multiple Myeloma; Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrazoles; Pyridones; Pyrimidinones; Thiophenes; Tumor Burden | 2015 |
3 other study(ies) available for thiophenes and trametinib
| Article | Year |
|---|---|
MEK inhibitors block growth of lung tumours with mutations in ataxia-telangiectasia mutated.
Topics: Animals; Ataxia Telangiectasia Mutated Proteins; Benzamides; Cell Line, Tumor; Cell Proliferation; Diphenylamine; Humans; Lung Neoplasms; Mice, Nude; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Pyridones; Pyrimidinones; ras Proteins; RNA Interference; Thiophenes; Urea; Xenograft Model Antitumor Assays | 2016 |
Clinical resistance associated with a novel MAP2K1 mutation in a patient with Langerhans cell histiocytosis.
Topics: Adolescent; Adrenal Cortex Hormones; Butadienes; Combined Modality Therapy; Cytarabine; Disease Progression; Drug Resistance; Drug Therapy, Combination; Enzyme Activation; Exons; HEK293 Cells; Hematopoietic Stem Cell Transplantation; Histiocytosis, Langerhans-Cell; Humans; Male; MAP Kinase Kinase 1; MAP Kinase Signaling System; Molecular Targeted Therapy; Mutation; Nitriles; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Pyrazoles; Pyridones; Pyrimidinones; Recombinant Fusion Proteins; Sequence Deletion; Thiophenes; Vincristine | 2018 |
A pharmacogenomic analysis using L1000CDS
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Gene Expression Regulation, Neoplastic; Glycogen Synthase Kinase 3 beta; Humans; Inhibitory Concentration 50; Male; Mice; Pancreatic Neoplasms; Pharmacogenomic Testing; Pyridones; Pyrimidines; Pyrimidinones; Signal Transduction; Thiophenes; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2019 |